Tyrosine is sold as a cognitive enhancer. It synthesizes dopamine. The marketing is simple: more dopamine precursor, better brain function. People take it voluntarily.
A study of 270,000 UK Biobank participants used Mendelian randomization to test whether genetically elevated tyrosine levels affect lifespan. Mendelian randomization exploits genetic variants as natural experiments. If a variant that increases tyrosine also predicts shorter life, the link is causal, not confounded by diet or lifestyle.
The result: genetically elevated tyrosine shortens male lifespan by approximately eleven months. No effect in women.
The mechanism runs through insulin resistance. Men have naturally higher baseline tyrosine levels. The additional load tips them into metabolic territory that accelerates aging. Women, with lower baselines, stay below the threshold where tyrosine becomes harmful. The same molecule is neutral in one body and toxic in another.
What matters here is the method. Observational studies of tyrosine supplementation face a standard problem: people who take supplements differ from people who do not in ways that correlate with health outcomes. Mendelian randomization strips this away. The genetic variants are assigned at conception. They correlate with tyrosine levels but not with the decision to take supplements. When the causal lens replaces the observational lens, the cognitive enhancer becomes a lifespan cost.
This is not a rare inversion. It is what happens when you apply a method capable of separating cause from association to a substance whose reputation was built on association. The supplement was never proven to help cognition through causal methods either. The entire framework — take precursor, get neurotransmitter, improve function — was plausible mechanism without causal evidence. When causal evidence arrives, it points the other way.
Note (2026-11-16; checked against a News-Medical report of the Aging paper, 'The role of phenylalanine and tyrosine in longevity: a cohort and Mendelian randomization study', not the paper's full text): the report says the study examined circulating tyrosine and genetically predicted higher tyrosine, did not test tyrosine supplements, and found genetically predicted higher tyrosine associated with shorter lifespan in both men and women with the clearest evidence in men, women's results being 'less consistent across Mendelian randomization methods'; the essay says no effect in women. On mechanism it says one potential pathway is tyrosine-mediated insulin resistance, where the essay says the mechanism runs through insulin resistance. It lists sample overlap that may introduce bias, applicability mainly to people with higher levels, and that circulating levels may not reflect dietary intake, and it says the findings do not support a long-term longevity benefit from tyrosine supplementation, which is not the same as showing that the supplement shortens life, the essay's 'the cognitive enhancer becomes a lifespan cost'. The report gives no figure in months; the eleven months I did not confirm here. The essay's account of men tipping over a baseline threshold, and of the method showing the supplement was never helpful for cognition, is its own.